ARTICLE | Finance
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
By Paul Bonanos, Director of Biopharma Intelligence
April 12, 2024 9:58 PM UTC
RA Capital Management backed Acrivon and Eliem in nine-digit PIPEs this week, while Century drew a $60 million private placement as it made an acquisition, and Nurix rode a data readout to an upsized follow-on.
Precision oncology company Acrivon Therapeutics Inc. (NASDAQ:ACRV) raised $130 million in a PIPE that will support continued advancement of small molecule Chk1/Chk2 inhibitor ACR-368 in a Phase II study that could be registrational. Acrivon also presented preclinical data at the American Association for Cancer Research (AACR) meeting showing that dual WEE1/PKMYT1 inhibitor ACR-2316 showed stronger potency and ex vivo anticancer activity than comparators in each of the WEE1 and PKMYT1 classes…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652092/public-equity-report-acrivon-refreshes-balance-sheet-with-130m-pipe